We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Antisense Therapy Lowers Levels of Pathogenic Tau Protein in Models

By LabMedica International staff writers
Posted on 08 Feb 2017
Print article
Image: Researchers have synthesized an antisense oligonucleotide (ASO) that can lower tau levels and prevent some neurological damage. In neurons that contain the ASO (above, in red) there are no tau tangles (in green) (Photo courtesy of Dr. Sarah DeVos, Washington University School of Medicine).
Image: Researchers have synthesized an antisense oligonucleotide (ASO) that can lower tau levels and prevent some neurological damage. In neurons that contain the ASO (above, in red) there are no tau tangles (in green) (Photo courtesy of Dr. Sarah DeVos, Washington University School of Medicine).
Antisense therapy was used to reverse the damage caused by accumulation of tau protein in mouse and monkey models of neurodegenerative diseases.

Accumulation of hyperphosphorylated tau protein directly correlates with cognitive decline in Alzheimer’s disease and other primary tauopathies. One therapeutic strategy may be to reduce total tau expression.

To explore this approach, investigators at Washington University School of Medicine genetically engineered a line of mice that produced a mutant form of human tau protein that readily aggregated into pathogenic tangles. These mice start showing tau tangles at around six months of age and exhibited some neuronal damage by nine months.

In order to reduce the amount of tau protein produced by the mice, the investigators employed antisense oligonucleotides (ASOs) that had been designed to bind to specific messenger RNA (mRNA) in the neurons and prevent the synthesis of tau. They reported in the January 25, 2017, online edition of the journal Science Translational Medicine that the ASO selectively decreased human tau mRNA and protein in mice expressing mutant P301S human tau. After reduction of human tau in this mouse model of tauopathy, fewer tau inclusions developed, and preexisting phosphorylated tau pathology was reversed. The resolution of tau pathology was accompanied by the prevention of hippocampal volume loss, neuronal death, and nesting deficits. In addition, mouse survival was extended, and pathological tau seeding was reversed.

To augment the mouse studies, the investigators treated groups of healthy cynomolgus monkeys with two doses of placebo or ASO, one week apart, directly into the cerebrospinal fluid that surrounds the spinal cord and brain. Two weeks later, the amount of tau protein and RNA in the monkeys' brains and cerebrospinal fluid was measured. Results revealed that the ASO treatment reduced both tau RNA and protein in the brain, and this reduction was mirrored in the cerebrospinal fluid.

"Tau tangles correlate with cognitive decline in several diseases," said senior author Dr. Timothy Miller, professor of neurology at Washington University School of Medicine. "This is a promising new approach to lowering tau, but we have to test whether it is safe in people, and whether it actually lowers tau, as it is designed to do, before we get to the question of whether it has any effect on the disease. But everything we have seen so far says that this is worth investigating as a potential treatment for people."

"We have shown that this molecule lowers levels of the tau protein, preventing and, in some cases, reversing the neurological damage. This compound is the first that has been shown to reverse tau-related damage to the brain that also has the potential to be used as a therapeutic in people. The monkey study showed us that lower tau in the cerebrospinal fluid correlates with lower tau in the brain. This is important if we are going to evaluate this treatment approach in people, because there is no non-invasive way of measuring tau levels in the brain. This correlation tells us that we can use levels of tau in the cerebrospinal fluid as a proxy for levels of tau in the brain."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.